Doxorubicin and Cyclophosphamide Plus Paclitaxel With or Without Trastuzumab in Treating Women With Node-Positive Breast Cancer That Overexpresses HER2

Completed · Phase 3

Conditions studied: Breast Cancer

In brief

RATIONALE: Drugs used in chemotherapy, such as doxorubicin, cyclophosphamide, and paclitaxel, use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. It is not yet known whether combination chemotherapy plus trastuzumab is more effective than combination chemotherapy alone for treating breast cancer. PURPOSE: This randomized phase III trial is studying how well giving combination chemotherapy together with trastuzumab works compared to combination chemotherapy alone in treating women with node-positive stage II or stage IIIA breast cancer that overexpresses HER2.

Key facts

Study ID

NCT00004067

Run by

NSABP Foundation Inc

People needed

2130

Starts

2000-02-01

Expected to finish

2019-11-01

Last updated by the study team

2021-04-29

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• The patient must have a life expectancy of at least 10 years, excluding her diagnosis of breast cancer. (Comorbid conditions should be taken into consideration, but not the diagnosis of breast cancer.)
• The interval between the last surgery for breast cancer treatment (lumpectomy, mastectomy, axillary dissection, or re-excision of lumpectomy margins) and randomization must be less than or equal to 84 days.
• All of the following staging criteria must be met:
• Primary tumor must be T1-3 by clinical and pathologic evaluation.
• Ipsilateral nodes must be cN0-1 by clinical evaluation.
• Ipsilateral nodes must be pN1, pN2a, or pN3a by pathologic evaluation.
• M0
• Patients must have undergone either a total mastectomy and an axillary dissection or a lumpectomy and an axillary dissection. Sentinel node biopsy is permitted, but must be followed by an axillary dissection.
• The tumor must be invasive adenocarcinoma on histologic examination.
• The tumor must be determined to be HER2-positive prior to randomization. Assays performed using fluorescent in situ hybridization (FISH) require gene amplification to be eligible. Assays using immunohistochemistry (IHC) must be performed at an NSABP-approved reference laboratory and require a strongly positive staining score.
• Patients must have an analysis of both estrogen and progesterone receptors performed on the primary tumor prior to randomization. "Marginal," "borderline," etc., results (i.e., those not definitely negative) will also be considered positive regardless of the methodology used.
• At the time of randomization, the patient must have had the following: history and physical exam, EKG, and PA and lateral chest x-ray within the past 3 months; and a bilateral mammogram (or unilateral if patient has had a mastectomy) and a pelvic exam (for women who have a uterus and who will be taking tamoxifen) within the past year.
• Within 3 months prior to entry, the patient must have a baseline left ventricular ejection fraction (LVEF) measured by MUGA scan equal to or greater than the lower limit of normal for the radiology facility. (If LVEF is > 75%, the investigator should consider having the LVEF determination reviewed prior to randomization. Following randomization, the LVEF determination may be reviewed up until the time of the post-AC MUGA. Please note that if a more accurate value is obtained from the review of the baseline MUGA, the corrected value must be submitted to the NSABP Biostatistical Center before the post-AC MUGA is performed.)
• At the time of randomization:
• The postoperative absolute neutrophil count (ANC) must be ≥ 1500/mm3 (or <1500/mm3 if, in the opinion of the investigator, this represents an ethnic or racial variation of normal).
• Postoperative platelet count must be ≥ 100,000/mm3. Significant underlying hematologic disorders must be excluded when the platelet count is above the upper limit of normal for the lab.
• There must be postoperative evidence of adequate hepatic function, i.e., total bilirubin must be ≤ ULN for the lab unless the patient has a chronic grade 1 bilirubin elevation (>ULN to ≤1.5 x ULN) due to Gilbert's disease or similar syndrome; and alkaline phosphatase must be <2.5 times the ULN for the lab; and the serum glutamic-oxaloacetic transaminase (SGOT [AST]) must be <1.5 times the ULN for the lab.
• There must be postoperative evidence of adequate renal function (serum creatinine within or less than the institution's normal range).
• Patients must have no clinical or radiologic evidence of metastatic disease. Suspicious findings must be confirmed as benign by radiologic evaluation or biopsy. A patient with skeletal pain is eligible for inclusion in the study if bone scan and/or roentgenological examination fails to disclose metastatic disease.
• Patients with a history of non-breast malignancies are eligible if they have been disease-free for 5 or more years prior to randomization and are deemed by their physician to be at low risk for recurrence. Patients with the following cancers are eligible if diagnosed and treated within the past 5 years: carcinoma in situ of the cervix, melanoma in situ, and basal cell and squamous cell carcinoma of the skin.
• Prior to randomization, the investigator must designate whether the patients who had a lumpectomy will receive local or locoregional radiation therapy. For patients who had a mastectomy, the investigator must designate whether or not the patient will receive radiation therapy. (Pre-randomization discussion and/or consultation with a radiation oncologist is encouraged.) Note: Irradiation of any internal mammary nodes is prohibited in this trial.
• Special conditions for eligibility of lumpectomy patients: irradiation and surgery
• Patients treated by lumpectomy and axillary node dissection to be followed by breast radiation therapy must meet all the eligibility criteria in addition to the following: Generally, lumpectomy should be reserved for tumors <5 cm. However, at the investigator's discretion, patients treated with lumpectomy for tumors ≥ 5 cm are eligible. The margins of the resected specimen must be histologically free of invasive tumor and DCIS as determined by the local pathologist. In patients in whom pathologic examination demonstrates tumor present at the line of resection, additional operative procedures may be performed to obtain clear margins. This is permissible even if axillary dissection has been performed. Patients in whom tumor is still present at the resected margin after re-excision(s) must undergo total mastectomy to be eligible. Whole breast irradiation is required. Irradiation of regional lymph nodes is optional, but partial breast irradiation and irradiation of any internal mammary nodes are prohibited in this trial. Intent to irradiate the axilla or other regional node groups must be declared by the investigator prior to randomization for stratification purposes.
• Special conditions for eligibility of mastectomy patients: irradiation. The decision to use locoregional irradiation in patients who have undergone total mastectomy and axillary node dissection must be declared by the investigator prior to randomization for stratification purposes. Failure to adhere to the radiation therapy plan will be a protocol violation.

You may not qualify if…

• Bilateral malignancy or a mass or mammographic abnormality in the opposite breast suspicious for malignancy unless there is biopsy proof that the mass is not malignant.
• Primary tumor staged as T4 for any reason.
• Nodes staged as clinical N2 or N3 for any reason and nodes staged as pathologic pN2b, pN3b, or pN3c.
• Prior history of breast cancer, including DCIS (patients with a history of lobular carcinoma in situ [LCIS] are eligible).
• Treatment including radiation therapy, chemotherapy, biotherapy, and/or hormonal therapy administered for the currently diagnosed breast cancer prior to randomization. The only exception is hormonal therapy, which may have been given for up to a total of 28 days anytime after diagnosis and before randomization. In such a case, hormonal therapy must stop at or before randomization and be re-started if indicated following chemotherapy.
• Prior anthracycline or taxane therapy for any malignancy.
• Any sex hormonal therapy, e.g., birth control pills, ovarian hormonal replacement therapy, etc. (These patients are eligible only if this therapy is discontinued prior to randomization.)
• Therapy with any hormonal agents such as raloxifene (Evista®), tamoxifen, or other selective estrogen receptor modulators (SERMs), either for osteoporosis or prevention. (Patients are eligible only if these medications are discontinued prior to randomization. These medications are not permitted while on the study except for the use of tamoxifen as described in the protocol)
• Nonmalignant systemic disease (cardiovascular, renal, hepatic, etc.) that would preclude a patient from being subjected to any of the treatment options or would prevent prolonged follow-up.
• Cardiac disease that would preclude the use of Adriamycin, Taxol or Herceptin. This includes:
• Active cardiac disease:
• angina pectoris that requires the use of antianginal medication;
• cardiac arrhythmia requiring medication;
• severe conduction abnormality;
• clinically significant valvular disease;
• cardiomegaly on chest x-ray;
• ventricular hypertrophy on EKG; or
• patients with poorly controlled hypertension, i.e., diastolic greater than 100 mm/Hg. (Patients with hypertension who are well controlled on medication are eligible for entry.)
• History of cardiac disease:
• myocardial infarction documented as a clinical diagnosis or by EKG or any other tests;
• documented congestive heart failure; or
• documented cardiomyopathy.
• Psychiatric or addictive disorders that would preclude obtaining informed consent.
• Pregnancy or lactation at the time of proposed randomization. This protocol excludes pregnant or lactating women based on the fetal toxicity of both tamoxifen and Taxol which are listed as Pregnancy Category D agents. Pregnant women who received tamoxifen have experienced fetal deaths, birth defects, spontaneous abortions, and vaginal bleeding. Women of reproductive potential must agree to use an effective barrier method of contraception. Hormonal birth control methods are not permitted.
• Sensory/motor neuropathy ≥ grade 2, as defined by the NCI's Common Toxicity Criteria version 2.0.

Where it is running

• Providence Alaska Medical Center — Anchorage, Alaska, United States
• CCOP - Western Regional, Arizona — Phoenix, Arizona, United States
• City of Hope Comprehensive Cancer Center — Duarte, California, United States
• Sutter Health Western Division Cancer Research Group — Greenbrae, California, United States
• Scripps Cancer Center at Scripps Clinic — La Jolla, California, United States
• Loma Linda University Cancer Institute at Loma Linda University Medical Center — Loma Linda, California, United States
• Pacific Shores Medical Group Comprehensive Hematology-Oncology Services - Long Beach — Long Beach, California, United States
• CCOP - Bay Area Tumor Institute — Oakland, California, United States
• Chao Family Comprehensive Cancer Center at University of California Irvine Medical Center — Orange, California, United States
• Comprehensive Cancer Center at Desert Regional Medical Center — Palm Springs, California, United States
• Sutter Cancer Center — Sacramento, California, United States
• Kaiser Permanente Medical Center/Kaiser Foundation Hospital - San Diego — San Diego, California, United States
• CCOP - Santa Rosa Memorial Hospital — Santa Rosa, California, United States
• Kaiser Permanente Medical Center - Vallejo — Vallejo, California, United States
• University of Colorado Cancer Center at University of Colorado Health Sciences Center — Denver, Colorado, United States
• CCOP - Colorado Cancer Research Program, Incorporated — Denver, Colorado, United States
• Carole and Ray Neag Comprehensive Cancer Center at the University of Connecticut Health Center — Farmington, Connecticut, United States
• Helen and Harry Gray Cancer Center at Hartford Hospital — Hartford, Connecticut, United States
• CCOP - Christiana Care Health Services — Wilmington, Delaware, United States
• Morton Plant Hospital — Clearwater, Florida, United States
• Halifax Medical Center — Daytona Beach, Florida, United States
• Baptist Cancer Institute - Jacksonville — Jacksonville, Florida, United States
• University of Miami Sylvester Comprehensive Cancer Center — Miami, Florida, United States
• CCOP - Mount Sinai Medical Center — Miami Beach, Florida, United States
• Comprehensive Cancer Institute — Huntsville, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.